The dual targeting of BCL2 (Venetoclax) and MCL-1 (S63845) was also suggested as an effective treatment for patients with myeloma, as both had little effect as single agents but, in combination at low doses, they were able to significantly increase levels of apoptosis. Here, BCL2 is linked to plasma cell myeloma.